Lilly to acquire AtaiBeckley to enhance treatment-resistant depression therapies
Eli Lilly is acquiring AtaiBeckley to advance therapies targeting treatment-resistant depression.
Asset / Drug
Drug and asset intelligence for BPL-003 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.